Veru (VERU) News Today

Veru Inc. (VERU) shares have declined amid mixed updates on its clinical programs, earnings results and analyst revisions. Investors are parsing:

• Positive Sentiment: Veru reported positive efficacy and safety data from the Phase 2b QUALITY and QUALITY Maintenance Extension studies, showing that adding enobosarm to semaglutide preserved lean mass and enhanced fat loss. GlobeNewswire Release
• Positive Sentiment: The company beat Q3 EPS estimates with a loss of $0.50 per share versus the expected $0.55 loss, reinforcing operational improvements. Press Release
• Neutral Sentiment: Analysts preview expectations for Veru’s Q3 2025 earnings report, outlining key catalysts for the upcoming release. Yahoo Finance Preview
• Neutral Sentiment: Veru published its full Q3 2025 financial results and clinical program update, summarizing quarterly performance. FinanzNachrichten Article
• Neutral Sentiment: Veru’s Q3 2025 earnings call transcript is now available, providing detailed insights from management on pipeline progress. Seeking Alpha Transcript
• Negative Sentiment: Veru’s shares hit a new 12-month low amid profit-taking and uncertainty around near-term catalysts. MarketBeat Article
• Negative Sentiment: The board approved a 1-for-10 reverse stock split, reducing share count and potentially impacting liquidity. MSN Article
• Negative Sentiment: Raymond James cut its price target on VERU to $20 from $30, signaling lowered expectations despite retaining an outperform rating. Benzinga